Product details
Background：Sibrotuzumab (also known as BIBH 1) is a humanized monoclonal antibody (mAb) which has the high affinity to bind to fibroblast activation protein (FAP), which is highly expressed by stroma cells of tumors. In addition, it was intended and developed by Boehringer Ingelheim Pharma KG for the treatment of cancer. Firstly, this drug was designed to fight against various malignancies, such as colorectal, non-small cell lung, breast, as well as head and neck cancer. However, it is disappointing that in 2003 it failed a phase II clinical trial for metastatic colorectal cancer. At present, there is no relevant clinically approved information disclosure.
• The fibroblast activation protein alpha as a biomarker of pulmonary fibrosis., PMID:39364020
• Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin., PMID:21251197
• Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein., PMID:16223769
• Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV., PMID:17174263
• Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design., PMID:19402713
• Circulating concentrations of fibroblast activation protein α in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA., PMID:23932048
• Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis., PMID:24034420
